Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)Rodolfo Passalacqua, Caterina Caminiti, Debora Pezzuolo et al.|Journal of Clinical Oncology|2005Cited by 3
Radiofrequency echographic multi-spectrometry for early bone health: The REMS-bone study protocol (Trial acronym: REMS-bone)Serafina Perrone, T. Ghi, Giorgia Pepe et al.|Global Pediatrics|2025Cited by 3
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP studyCaterina Caminiti, Francesco Perrone, Giuseppe Maglietta et al.|The Breast|2024Cited by 2
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patientsMaria Lucia Iacovino, Francesco Perrone, Laura Arenare et al.|Lung Cancer|2026Cited by 0